{"content":"<li class=\"n-box-item date-title\" data-end=\"1490846399\" data-start=\"1490760000\" data-txt=\"Sunday, December 22, 2019\">Wednesday, March 29, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3254315\" data-ts=\"1490844231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254315-interpace-diagnostics-higher-35-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace Diagnostics higher 35% on Q4 results</a></h4><ul><li>Interpace Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a>): Q4 EPS of $3.25</li><li>Revenue of $3.12M (+21.9% Y/Y)</li><li>Shares <font color='green'>+35.3%</font> AH.</li><li><a href=\"https://seekingalpha.com/pr/16783563-interpace-diagnostics-group-announces-timing-earnings-release-investor-conference-call\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3254315\" data-linked=\"Interpace Diagnostics higher 35% on Q4 results\" data-tweet=\"$IDXG - Interpace Diagnostics higher 35% on Q4 results https://seekingalpha.com/news/3254315-interpace-diagnostics-higher-35-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3254315-interpace-diagnostics-higher-35-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254300\" data-ts=\"1490823517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254300-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/EXTR' title='Extreme Networks, Inc.'>EXTR</a> <font color='green'>+14.7%</font>. <a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a> <font color='green'>+6.3%</font>. <a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color='green'>+6.1%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+4.7%</font>. <a href='https://seekingalpha.com/symbol/AREX' title='Approach Resources Inc.'>AREX</a> <font color='green'>+2.6%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='red'>-18.1%</font>. <a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='red'>-15.3%</font>. <a href='https://seekingalpha.com/symbol/CVE' title='Cenovus Energy, Inc.'>CVE</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/SIGM' title='Sigma Designs, Inc.'>SIGM</a> <font color='red'>-6.7%</font>. <a href='https://seekingalpha.com/symbol/WOR' title='Worthington Industries, Inc.'>WOR</a> <font color='red'>-5.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254300\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$EXTR $PRGS $COP - After Hours Gainers / Losers https://seekingalpha.com/news/3254300-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3254300-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254298\" data-ts=\"1490822814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SA\" target=\"_blank\">SA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254298-seabridge-gold-launches-1m-share-bought-deal-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seabridge Gold launches 1M-share bought deal offering</a></h4><ul><li>Seabridge Gold (NYSEMKT:<a href='https://seekingalpha.com/symbol/SA' title='Seabridge Gold Inc'>SA</a>) <font color='red'>-2.5%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16785007-seabridge-gold-announces-14_3-million-bought-deal-offering-common-shares-concurrent-20_0\" target=\"_blank\">bought deal financing</a> for 1M common shares at C$14.30/share, with an underwriters option to purchase up to an additional 100K shares.</li><li>SA also announces a concurrent bought deal offering of 1M flow-through common shares at C$20/share, with an underwriters option to purchase up to an additional 100K shares.</li><li>SA says it plans to use the proceeds to continue to  advance the KSM and Iskut projects in British Columbia and for general corporate  purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254298\" data-linked=\"Seabridge Gold launches 1M-share bought deal offering\" data-tweet=\"$SA - Seabridge Gold launches 1M-share bought deal offering https://seekingalpha.com/news/3254298-seabridge-gold-launches-1m-share-bought-deal-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3254298-seabridge-gold-launches-1m-share-bought-deal-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254297\" data-ts=\"1490822704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXTR\" target=\"_blank\">EXTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254297-extreme-networks-buying-brocade-data-center-networking-sharesplus-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Extreme Networks buying Brocade data-center networking; shares +14%</a></h4><ul>   <li>Extreme Networks (<a href=\"http://seekingalpha.com/symbol/EXTR\" target=\"_blank\">EXTR</a> <font color='red'>-1.1%</font>) has gotten an after-hours boost, <font color='green'>up 14.2%</font>, after news that it's <a href=\"https://seekingalpha.com/pr/16784907-extreme-networks-acquire-brocades-data-center-networking-business\" target=\"_blank\">buying the data-center networking business</a> from Brocade (<a href=\"http://seekingalpha.com/symbol/BRCD\" target=\"_blank\">BRCD</a> <font color='red'>-0.2%</font>).</li>    <li>The deal's contingent on a successful takeover of Brocade by Broadcom (<a href=\"http://seekingalpha.com/symbol/AVGO\" target=\"_blank\">AVGO</a> <font color='green'>+0.2%</font>).</li>    <li>Extreme will pay $55M in cash -- $35M at closing, and $20M in deferred payments, along with potential performance-based payments over a five-year term.</li>    <li>The company expects the deal to be accretive to cash flow and earnings in fiscal 2018, and to generate more than $230M in incremental annualized revenue.</li>    <li>Extreme recently agreed to be <a href=\"https://seekingalpha.com/news/3249370-extreme-networks-plus-6_6-percent-deal-buy-avaya-networking-100m\" target=\"_blank\">stalking-horse bidder for Avaya's networking business</a> ($200M annualized revenue expected) and last fall closed its acquisition of Zebra Technology's wireless LAN business.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254297\" data-linked=\"Extreme Networks buying Brocade data-center networking; shares +14%\" data-tweet=\"$EXTR $EXTR $BRCD - Extreme Networks buying Brocade data-center networking; shares +14% https://seekingalpha.com/news/3254297-extreme-networks-buying-brocade-data-center-networking-sharesplus-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3254297-extreme-networks-buying-brocade-data-center-networking-sharesplus-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254291\" data-ts=\"1490821190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGS\" target=\"_blank\">PRGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254291-progress-softwareplus-9_7-on-q1-beat-names-new-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progress Software +9.7% on Q1 beat; names new CFO</a></h4><ul>   <li>Progress Software (<a href=\"http://seekingalpha.com/symbol/PRGS\" target=\"_blank\">PRGS</a> <font color='green'>+1.3%</font>) has traded <font color='green'>up 9.7%</font> after hours after <a href=\"https://seekingalpha.com/news/3254275-progress-software-beats-0_08-beats-revenue\" target=\"_blank\">fiscal Q1 results</a> where it beat on top and bottom lines and named a new chief financial officer.</li>    <li>The company tapped Paul Jalbert as the new CFO, and he immediately pointed to strong free cash flow of $43M, up from $22.7M, \"driven largely by collections that resulted in an excellent DSO performance, a testament to the quality of our products and services.\"</li>    <li>Revenue inched up slightly to $91.2M, while operating margin climbed to 30% from a previous 24%.</li>    <li>Cash, equivalents and short-term investments came to $264.2M. DSO was 48 days vs. a year-ago 59 days, and 50 days at the end of the previous quarter.</li>    <li>For Q2, it's guiding to revenues of $89M-$92M (slightly below consensus for $93.1M) and non-GAAP EPS of $0.35-$0.37 (vs. consensus for $0.37). For the full year, it still sees revenue of $388M-$396M (vs. $391M expected) and EPS of $1.64-$1.69 (vs. consensus for $1.66).</li>    <li><a href=\"http://edge.media-server.com/m/p/c762dt3q\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16784920-progress-reports-2017-fiscal-first-quarter-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3254291\" data-linked=\"Progress Software +9.7% on Q1 beat; names new CFO\" data-tweet=\"$PRGS - Progress Software +9.7% on Q1 beat; names new CFO https://seekingalpha.com/news/3254291-progress-softwareplus-9_7-on-q1-beat-names-new-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3254291-progress-softwareplus-9_7-on-q1-beat-names-new-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254289\" data-ts=\"1490820697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANTH\" target=\"_blank\">ANTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254289-antheras-sollpura-on-par-pancreaze-in-extension-phase-of-late-stage-study-in-certain-cf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anthera&#39;s Sollpura on par with Pancreaze in extension phase of late-stage study in certain CF patients; shares ahead 9% after hours</a></h4><ul><li>Nano cap Anthera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16784889-anthera-announces-positive-results-extension-period-solution-study-sollpura\" target=\"_blank\">announcement </a>of positive results from the extension phase of a Phase 3 non-inferiority clinical trial, SOLUTION, assessing Sollpura (liprotamase) compared to <a href=\"https://www.goodrx.com/pancreaze/what-is\" target=\"_blank\">Pancreaze </a>in cystic fibrosis &#40;CF&#41; patients with exocrine pancreatic insufficiency &#40;EPI&#41;.</li><li>During the extension period (week 7 through week 20) all patients in both groups maintained their weight. Increases in weight and height were observed in patients less than 17 years of age in both cohorts. Sollpura was well-tolerated throughout the treatment period.</li><li><a href=\"https://www.anthera.com/product-pipeline/sollpura/\" target=\"_blank\">Sollpura </a>is a non-porcine pancreatic enzyme replacement therapy &#40;PERT&#41; containing a proprietary engineered cross-linked formulation of crystalline lipase, crystalline protease and amorphous amylase. The company says its solubility and stability offers a more patient-friendly alternative for those who cannot swallow multiple pills or require gastric tubes in order to maintain their nutritional health.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254289\" data-linked=\"Anthera&#39;s Sollpura on par with Pancreaze in extension phase of late-stage study in certain CF patients; shares ahead 9% after hours\" data-tweet=\"$ANTH - Anthera&#39;s Sollpura on par with Pancreaze in extension phase of late-stage study in certain CF patients; shares ahead 9% after hours https://seekingalpha.com/news/3254289-antheras-sollpura-on-par-pancreaze-in-extension-phase-of-late-stage-study-in-certain-cf?source=tweet\" data-url=\"https://seekingalpha.com/news/3254289-antheras-sollpura-on-par-pancreaze-in-extension-phase-of-late-stage-study-in-certain-cf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254282\" data-ts=\"1490819759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXFO\" target=\"_blank\">EXFO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254282-exfo-fiscal-q2-revenues-miss-despite-12-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EXFO fiscal Q2 revenues miss despite 12% growth</a></h4><ul>   <li>EXFO (<a href=\"http://seekingalpha.com/symbol/EXFO\" target=\"_blank\">EXFO</a> <font color='green'>+3.5%</font>) is <font color='red'>off 15%</font> in a light postmarket trade following <a href=\"https://seekingalpha.com/news/3254267-exfo-eps-0_02\" target=\"_blank\">fiscal Q2 results</a> where revenues missed slightly despite gains of 12%.</li>    <li>EBITDA fell to $4.9M from $5.3M, missing an expected $5.3M; it made up 8.1% of sales.</li>    <li>Bookings were $55.9M vs. a year-ago $59.7M; book-to-bill ratio came to 0.93. Year-to-date bookings growth is up 3% Y/Y.</li>    <li>After the quarter ended, the company acquired Ontology Systems for $7.6M net of cash along with a sales-based earnout.</li>    <li>For Q3, it's expecting sales of (U.S. dollars) $58M-$63M (slightly below consensus for $64M) and EPS of -$0.02 to $0.02 (below expected $0.09).</li>    <li><a href=\"http://edge.media-server.com/m/p/i58sokdc\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16784901-exfo-reports-second-quarter-results-fiscal-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3254282\" data-linked=\"EXFO fiscal Q2 revenues miss despite 12% growth\" data-tweet=\"$EXFO - EXFO fiscal Q2 revenues miss despite 12% growth https://seekingalpha.com/news/3254282-exfo-fiscal-q2-revenues-miss-despite-12-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3254282-exfo-fiscal-q2-revenues-miss-despite-12-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254279\" data-ts=\"1490819493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254279-tonix-pharma-readies-equity-offering-shares-off-14-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma readies equity offering; shares off 14% after hours</a></h4><ul><li>Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) slumps&nbsp;<font color='red'>14%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16784899-tonix-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">planned stock offering</a>. Price, volume and terms have yet to be announced. Net proceeds will fund pipeline development, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254279\" data-linked=\"Tonix Pharma readies equity offering; shares off 14% after hours\" data-tweet=\"$TNXP - Tonix Pharma readies equity offering; shares off 14% after hours https://seekingalpha.com/news/3254279-tonix-pharma-readies-equity-offering-shares-off-14-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3254279-tonix-pharma-readies-equity-offering-shares-off-14-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254276\" data-ts=\"1490819139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVE\" target=\"_blank\">CVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254276-cenovus-to-buy-conocophillips-50-stake-in-fccl-assets-for-c-17_7b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cenovus to buy ConocoPhillips&#39; 50% stake in FCCL, other assets for C$17.7B</a></h4><ul>     <li>Cenovus Energy (NYSE:<a href='https://seekingalpha.com/symbol/CVE' title='Cenovus Energy, Inc.'>CVE</a>) <a href=\"https://seekingalpha.com/pr/16784906-cenovus-double-production-reserves-canada\" target=\"_blank\">agrees to acquire</a> ConocoPhillips' (NYSE:<a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a>) 50% interest in the Foster Creek Christina Lake partnership, the companies' jointly owned oil sands venture operated by CVE, and the majority of COP's Deep Basin conventional assets in Alberta and British Columbia, for C$17.7B (US$14.1B) in cash and stock.</li><li>CVE says the assets have a combined forecast 2017 production of ~298K boe/day, and should result in  an 18% increase in 2018 adjusted funds flow  per share compared with its original 2018 forecast.</li>     <li>COP <a href=\"https://seekingalpha.com/pr/16784909-conocophillips-announces-sale-foster-creek-christina-lake-partnership-interest-western-canada\" target=\"_blank\">also will receive</a> five years of uncapped contingent payments, triggered when Western Canada Select crude prices exceed C$52/bbl.</li>     <li>To help fund the deal, CVE is launching a <a href=\"https://seekingalpha.com/pr/16784908-cenovus-announces-3_0-billion-bought-deal-offering-common-shares\" target=\"_blank\">bought-deal offering </a>to sell 187.5M common shares at C$16/share for ~C$3B in expected gross proceeds; the underwriters will have an over-allotment option to purchase up to an additional 28.125M shares.</li><li>CVE <font color='red'>-8.2%</font>, COP&nbsp;<font color='green'>+6.1%</font>&nbsp;AH.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254276\" data-linked=\"Cenovus to buy ConocoPhillips&#39; 50% stake in FCCL, other assets for C$17.7B\" data-tweet=\"$CVE $CVE $COP - Cenovus to buy ConocoPhillips&#39; 50% stake in FCCL, other assets for C$17.7B https://seekingalpha.com/news/3254276-cenovus-to-buy-conocophillips-50-stake-in-fccl-assets-for-c-17_7b?source=tweet\" data-url=\"https://seekingalpha.com/news/3254276-cenovus-to-buy-conocophillips-50-stake-in-fccl-assets-for-c-17_7b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254274\" data-ts=\"1490818567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIGM\" target=\"_blank\">SIGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254274-sigma-designsminus-11-revenues-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sigma Designs -11% as revenues disappoint</a></h4><ul>   <li>System-on-chip provider Sigma Designs (NASDAQ:<a href='https://seekingalpha.com/symbol/SIGM' title='Sigma Designs, Inc.'>SIGM</a>) is <font color='red'>off 10.9%</font> after hours following <a href=\"https://seekingalpha.com/news/3254263-sigma-designs-eps-line-misses-revenue\" target=\"_blank\">Q4 results</a> that missed revenue expectations after sales dropped 17%.</li>    <li>EPS was in line, though the company swung to a net loss, and non-GAAP gross margin grew to 50.6% from a previous-year 49.6%. Operating expenses fell to $26M from $27.4M.</li>    <li>The company's transitioning to an Internet-of-Things focus, says CEO Thinh Tran, and that will include a transition of development to lower-cost regions. The company's started a program to cut annual operating expenses by about 10% this year.</li>    <li><a href=\"http://www.sigmadesigns.com/IR\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16784884-sigma-designs-inc-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3254274\" data-linked=\"Sigma Designs -11% as revenues disappoint\" data-tweet=\"$SIGM - Sigma Designs -11% as revenues disappoint https://seekingalpha.com/news/3254274-sigma-designsminus-11-revenues-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3254274-sigma-designsminus-11-revenues-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254270\" data-ts=\"1490818397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254270-tailspin-for-lululemon-after-warning-on-slow-start-to-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tailspin for Lululemon after warning on &#39;slow start&#39; to 2017</a></h4><ul> <li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) reported solid sales growth for <a href=\"https://seekingalpha.com/pr/16784894-lululemon-athletica-inc-announces-fourth-quarter-full-year-fiscal-2016-results\" target=\"_blank\">Q4</a>, but missed profit estimates and is rattling investors with its full-year guidance.</li> <li>Comparable store sales rose 8% during the quarter to sail past the consensus estimate for a 5.3% rise.</li> <li>Gross margin during the quarter came in at 54.2% vs. 53.7% expected and 50.3% a year ago.</li> <li>Income as a percentage of revenue was up 130 bps to 24.9% of sales.</li> <li>Lululemon ended the quarter with 406 stores open, +17 Q/Q and +43 Y/Y.</li> <li>Looking ahead, Lululemon expects Q1 revenue of $510M to $515M vs. $553M consensus and Q1 EPS of $0.25 to $0.27 vs. $0.39 consensus. For the full year, revenue of $2.55B to $2.62B is expected vs. $2.62B consensus and EPS guidance arrives at $2.26 to $2.36 vs. $2.56 consensus. CEO Laurent Potdevin warns on the \"slow start\" to 2017.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254262-lululemon-athletica-misses-0_01-beats-revenue\" target=\"_blank\">Lululemon Athletica misses by $0.01, beats on revenue</a> (March 29)</li> <li>LULU <font color='red'>-15.54%</font> AH to $56.20 vs. a 52-week trading of 54.00 to $81.81.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254270\" data-linked=\"Tailspin for Lululemon after warning on &#39;slow start&#39; to 2017\" data-tweet=\"$LULU - Tailspin for Lululemon after warning on &#39;slow start&#39; to 2017 https://seekingalpha.com/news/3254270-tailspin-for-lululemon-after-warning-on-slow-start-to-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3254270-tailspin-for-lululemon-after-warning-on-slow-start-to-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254269\" data-ts=\"1490818350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNV\" target=\"_blank\">SNV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254269-synovus-in-talks-to-buy-financial-arm-of-cabelas-dow-jones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synovus in talks to buy financial arm of Cabela&#39;s - Dow Jones</a></h4><ul><li>As part of the deal, Synovus (NYSE:<a href='https://seekingalpha.com/symbol/SNV' title='Synovus Financial Corp.'>SNV</a>) would then sell the credit card unit to Capital One (NYSE:<a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a>), and keep the deposits.</li><li>Capital One earlier this year <a href=\"https://seekingalpha.com/news/3237891-opportunity-card-companies-capone-exits-cabelas-deal\" target=\"_blank\">walked away from</a> a deal with Cabela's (NYSE:<a href='https://seekingalpha.com/symbol/CAB' title='Cabela&#39;s Incorporated'>CAB</a>) as it didn't expect to receive regulatory approval.</li><li>The sale to Synovus would open the door for Cabela's acquisition by Bass Pro. Cabela's shot higher into the close, finishing&nbsp;<font color='green'>ahead by 12.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254269\" data-linked=\"Synovus in talks to buy financial arm of Cabela&#39;s - Dow Jones\" data-tweet=\"$SNV $SNV $COF - Synovus in talks to buy financial arm of Cabela&#39;s - Dow Jones https://seekingalpha.com/news/3254269-synovus-in-talks-to-buy-financial-arm-of-cabelas-dow-jones?source=tweet\" data-url=\"https://seekingalpha.com/news/3254269-synovus-in-talks-to-buy-financial-arm-of-cabelas-dow-jones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254259\" data-ts=\"1490817926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254259-hospitals-and-insurers-under-pressure-on-republicans-reboot-of-healthcare-bill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospitals and insurers under pressure on Republicans&#39; reboot of healthcare bill</a></h4><ul><li>Hospitals and insurers continue their up-and-down behavior in response to Republican lawmakers' efforts to pass the American Health Care Act. They plan another run next week.</li><li>Source: Bloomberg</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='red'>-1.1%</font>)(<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='red'>-1%</font>)(<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+0.2%</font>)(<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='red'>-0.7%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='red'>-0.3%</font>)(<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='red'>-1.4%</font>)(<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='red'>-1.2%</font>)(<a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='green'>+1.3%</font>)(<a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-14.3%</font>)(<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='red'>-2.3%</font>)(<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a> <font color='red'>-0.7%</font>)(<a href='https://seekingalpha.com/symbol/LPNT' title='LifePoint Health, Inc.'>LPNT</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='red'>-4.8%</font>)(<a href='https://seekingalpha.com/symbol/HCP' title='HCP, Inc.'>HCP</a>)(<a href='https://seekingalpha.com/symbol/SEM' title='Select Medical Holdings Corporation'>SEM</a> <font color='green'>+1.1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254259\" data-linked=\"Hospitals and insurers under pressure on Republicans&#39; reboot of healthcare bill\" data-tweet=\"$UNH $UNH $AET - Hospitals and insurers under pressure on Republicans&#39; reboot of healthcare bill https://seekingalpha.com/news/3254259-hospitals-and-insurers-under-pressure-on-republicans-reboot-of-healthcare-bill?source=tweet\" data-url=\"https://seekingalpha.com/news/3254259-hospitals-and-insurers-under-pressure-on-republicans-reboot-of-healthcare-bill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254256\" data-ts=\"1490817709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEVO\" target=\"_blank\">GEVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254256-gevo-misses-0_18-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gevo misses by $0.18, misses on revenue</a></h4><ul><li>Gevo (NASDAQ:<a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a>): Q4 EPS of -$1.14 <font color='red'>misses by $0.18</font>.</li><li>Revenue of $5.8M (-20.5% Y/Y) <font color='red'>misses by $1.34M</font>.</li><li>Shares <font color='green'>+13%</font>.</li><li><a href='https://seekingalpha.com/pr/16784857-gevo-reports-fourth-quarter-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3254256\" data-linked=\"Gevo misses by $0.18, misses on revenue\" data-tweet=\"$GEVO - Gevo misses by $0.18, misses on revenue https://seekingalpha.com/news/3254256-gevo-misses-0_18-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3254256-gevo-misses-0_18-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254250\" data-ts=\"1490816015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254250-snap-hits-positive-ground-after-winter-olympics-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap hits positive ground after Winter Olympics deal</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) has reversed field late today -- now <font color='green'>up 1.8%</font> after being <font color='red'>down as much as 4%</font> following cautious notes from <a href=\"https://seekingalpha.com/news/3254160-odeon-skeptical-hedge-funds-looking-short-snap\" target=\"_blank\">Odeon</a> and <a href=\"https://seekingalpha.com/news/3254227-barclays-starts-facebook-buy-snap-equal-weight\" target=\"_blank\">Barclays</a> -- after news of a deal tied to the <a href=\"https://www.wsj.com/articles/snap-inc-enters-partnership-with-nbcuniversal-for-2018-winter-olympics-1490807895\" target=\"_blank\">2018 Winter Olympics</a>.</li>    <li>The company has signed with NBCUniversal (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) to become a digital home for Olympic content, including related geofilters and Snapchat \"lenses.\" Ad commitments tied to the deal could come in the range of $50M-$75M, <em>The Wall Street Journal</em> reports.</li>    <li>The two had <a href=\"https://seekingalpha.com/news/3177756-snapchat-pioneering-deal-nbc-share-olympic-video\" target=\"_blank\">partnered last year with a deal</a> regarding highlights for the Rio Olympics, the first time NBC allowed Olympic video off its property.</li>    <li>Expanding on that arrangement, Snapchat will also carry coverage of the Winter Games that BuzzFeed will co-produce with NBC.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254250\" data-linked=\"Snap hits positive ground after Winter Olympics deal\" data-tweet=\"$SNAP $SNAP $CMCSA - Snap hits positive ground after Winter Olympics deal https://seekingalpha.com/news/3254250-snap-hits-positive-ground-after-winter-olympics-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3254250-snap-hits-positive-ground-after-winter-olympics-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>94&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254247\" data-ts=\"1490815573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRTO\" target=\"_blank\">CRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254247-criteominus-2_1-goldman-goes-neutral-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Criteo -2.1% as Goldman goes Neutral on valuation</a></h4><ul>   <li>Criteo (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>) is <font color='red'>off 2.1%</font> today, taking some edge off a strong 2017, after a Goldman Sachs downgrade to Neutral, from Buy.</li>    <li>That run (<font color='green'>up 21.8%</font> YTD) has prompted the new stance, since Goldman still sees solid fundamentals at the company amid a secular shift to digital, writes analyst Heath Terry.</li>    <li>A takeout isn't likely, since Criteo provides a strategic benefit as an alternative to Google/Facebook; Terry thinks at current valuation there's a 15-30% chance it gets acquired.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254247\" data-linked=\"Criteo -2.1% as Goldman goes Neutral on valuation\" data-tweet=\"$CRTO - Criteo -2.1% as Goldman goes Neutral on valuation https://seekingalpha.com/news/3254247-criteominus-2_1-goldman-goes-neutral-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3254247-criteominus-2_1-goldman-goes-neutral-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254244\" data-ts=\"1490814841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOFI\" target=\"_blank\">BOFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254244-bofi-lower-on-bankruptcy-filing-selloff-overdone-says-fbr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofI lower on bankruptcy filing; selloff overdone, says FBR</a></h4><ul><li>A bankruptcy filing alleged that a Quick Bridge loan issued through BofI (NYSE:<a href='https://seekingalpha.com/symbol/BOFI' title='BofI Holding, Inc.'>BOFI</a>) was invalid, but FBR's Bob Ramsey says the allegations are mostly aimed at Quick Bridge, not BofI. Further, this sort of charge from bankruptcy debtors is pretty normal.</li><li>He also notes the bankruptcy trustee is not a DOJ employee, <a href=\"https://www.streetinsider.com/Litigation/Bofl+Holding+%28BOFI%29+Ticks+Lower+on+Talk+of+Fraud+Suit/12719236.html\" target=\"_blank\">so a report that</a> this is a DOJ allegation against BofI is untrue.</li><li>BOFI was down double-digits earlier in the session, but has clawed back to a&nbsp;<font color='red'>4% loss</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254244\" data-linked=\"BofI lower on bankruptcy filing; selloff overdone, says FBR\" data-tweet=\"$BOFI - BofI lower on bankruptcy filing; selloff overdone, says FBR https://seekingalpha.com/news/3254244-bofi-lower-on-bankruptcy-filing-selloff-overdone-says-fbr?source=tweet\" data-url=\"https://seekingalpha.com/news/3254244-bofi-lower-on-bankruptcy-filing-selloff-overdone-says-fbr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254242\" data-ts=\"1490814354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFG\" target=\"_blank\">CFG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254242-citizens-financialminus-2_5-on-report-of-fabricated-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citizens Financial -2.5% on report of fabricated data</a></h4><ul><li>Part of the bank's turnaround plan is a program in which Citizens (<a href='https://seekingalpha.com/symbol/CFG' title='Citizens Financial Group'>CFG</a> <font color='red'>-2.5%</font>) invites customers into branches for a financial checkup. According to CFG, 400K such meetings were scheduled last year.</li><li>In <a href=\"https://www.wsj.com/articles/citizens-bankers-say-they-faked-data-for-customer-meeting-program-1490811468\" target=\"_blank\">a report from the WSJ</a>, eleven current and former branch employees across five states say they or others made up information about these meetings in order to meet aggressive goals set by the bank.</li><li>One former branch manager said \"no one was picking up the phone\" when employees were trying to make appointments, so eventually they just put random customers' names down on the appointment sheet.</li><li>After the fake appointment was supposed to have taken place, bankers than marked that the customer didn't show or didn't sign up for any new products.</li><li>Citizens says it has no data to suggest any shenanigans.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254242\" data-linked=\"Citizens Financial -2.5% on report of fabricated data\" data-tweet=\"$CFG - Citizens Financial -2.5% on report of fabricated data https://seekingalpha.com/news/3254242-citizens-financialminus-2_5-on-report-of-fabricated-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3254242-citizens-financialminus-2_5-on-report-of-fabricated-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254240\" data-ts=\"1490814123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254240-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EXAR' title='Exar Corporation'>EXAR</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254240\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$EXAR $SITO $EMAN - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3254240-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3254240-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254241\" data-ts=\"1490813755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USCR\" target=\"_blank\">USCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254241-u-s-concretes-recent-weakness-buying-opportunity-da-davidson-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Concrete&#39;s recent weakness a buying opportunity, DA Davidson says</a></h4><ul>     <li>U.S. Concrete (<a href='https://seekingalpha.com/symbol/USCR' title='US Concrete Inc.'>USCR</a> <font color='green'>+3.4%</font>) is higher after DA Davidson analyst Brent Thielman says its disclosure <a href=\"https://seekingalpha.com/news/3253367-u-s-concrete-minus-10-percent-suntrust-defending-stock\" target=\"_blank\">last week</a> of an auditor change and the CFO's resignation are unrelated and <a href=\"http://thefly.com/landingPageNews.php?id=2526774&amp;headline=USCR-US-Concrete-recent-weakness-a-buying-opportunity-says-DA-Davidson\" target=\"_blank\">raise unnecessary concerns</a>, and that it could not have hired Ernst &amp; Young if a material concern had existed.</li><li>According to The Fly.com, Thielman also says USCR has significant capital available to deploy, and could attract a new DVO with more extensive M&amp;A and/or materials industry experience.</li><li>The firm rates USCR as a Buy with an $80 price target, and views the recent pullback as a buying opportunity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254241\" data-linked=\"U.S. Concrete&#39;s recent weakness a buying opportunity, DA Davidson says\" data-tweet=\"$USCR - U.S. Concrete&#39;s recent weakness a buying opportunity, DA Davidson says https://seekingalpha.com/news/3254241-u-s-concretes-recent-weakness-buying-opportunity-da-davidson-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3254241-u-s-concretes-recent-weakness-buying-opportunity-da-davidson-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254233\" data-ts=\"1490811924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254233-eldorado-goldplus-9-on-better-olympias-sales-terms-canaccord-ups-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eldorado Gold +9% on better Olympias sales terms; Canaccord ups to Buy</a></h4><ul><li>Eldorado Gold (<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+9.2%</font>) is <a href=\"http://business.financialpost.com/investing/trading-desk/eldorado-gold-corp-upgraded-to-buy-as-olympias-on-track\" target=\"_blank\">upgraded to Buy</a> from Hold with a $5.50 price target at Canaccord Genuity after the company said it had received multiple tenders for <a href=\"https://seekingalpha.com/pr/16783653-eldorado-reports-olympias-phase-ii-improved-concentrate-sales-terms-commissioning-track\" target=\"_blank\">significantly better concentrate sales terms</a> for the phase two expansion of its Olympias project in Greece.</li><li>\"Underground development appears to be well advanced to support expanded production levels,\"&nbsp;Canaccord's Tony Lesiak writes, adding that commercial production at Olympias is expected to begin in H2 2017.</li><li>As a result of the improved terms and current zinc prices, the firm expects EGO's cash operating costs to come in below current company guidance of $230-$370/oz. from 2018 to 2022.</li><li>Also, Credit Suisse <a href=\"https://www.streetinsider.com/Analyst+Comments/Eldorado+Gold+Corp+%28EGO%29+PT+Raised+to+%245.25+at+Credit+Suisse%3B+Olympias+on+Track/12717527.html\" target=\"_blank\">raises</a> its EGO stock price target to $5.25 from $4.75 while maintaining an Outperform rating.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254233\" data-linked=\"Eldorado Gold +9% on better Olympias sales terms; Canaccord ups to Buy\" data-tweet=\"$EGO - Eldorado Gold +9% on better Olympias sales terms; Canaccord ups to Buy https://seekingalpha.com/news/3254233-eldorado-goldplus-9-on-better-olympias-sales-terms-canaccord-ups-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3254233-eldorado-goldplus-9-on-better-olympias-sales-terms-canaccord-ups-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254231\" data-ts=\"1490811082\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254231-mkm-rest-of-street-too-bullish-on-infinera-sharesminus-1_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MKM: Rest of Street too bullish on Infinera; shares -1.7%</a></h4><ul>   <li>Optimism around Infinera (<a href=\"http://seekingalpha.com/symbol/INFN\" target=\"_blank\">INFN</a> <font color='red'>-1.7%</font>) is <a href=\"http://blogs.barrons.com/techtraderdaily/2017/03/29/infinera-expectations-much-too-high-q2-at-risk-says-mkm/\" target=\"_blank\">running ahead of course</a>, argues MKM Partners' Michael Genovese, reiterating a Neutral stance on the stock.</li>    <li>The key long haul fiber market has just passed a spending cycle, he notes, and expectations for a burgeoning \"metro\" fiber market are hot: \"Success in next-gen Metro will be key, but we think it would be dangerous for investors to assume that once new Metro products come out it will be off to the races for revenues.\"</li>    <li>Genovese has a fair value estimate of $9, about 14% below today's price.</li>    <li>There's improvement ahead for sure, Genovese says: \"The bull case is revenues and GMs are bottoming in 1Q17, and financials should sharply improve from here driven by the new ICE4 chipset and multiple new DCI, Metro and LH product launches in 2017. We agree revenues and margins should sequentially improve through 2017, but we disagree about the magnitude.\"</li>    <li>Earlier this month, Goldman Sachs <a href=\"https://seekingalpha.com/news/3251636-infinera-upgraded-buy-goldman-sachs-plus-3_96-percent\" target=\"_blank\">boosted Infinera to Buy</a>, expecting new products to continue momentum from some revenue recognition boosts coming in Q2.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254231\" data-linked=\"MKM: Rest of Street too bullish on Infinera; shares -1.7%\" data-tweet=\"$INFN - MKM: Rest of Street too bullish on Infinera; shares -1.7% https://seekingalpha.com/news/3254231-mkm-rest-of-street-too-bullish-on-infinera-sharesminus-1_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3254231-mkm-rest-of-street-too-bullish-on-infinera-sharesminus-1_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254230\" data-ts=\"1490810916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXLG\" target=\"_blank\">DXLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254230-apparel-stocks-get-day-in-sun\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apparel stocks get their day in the sun</a></h4><ul> <li>Border tax fears continue to seep away from the retail sector as more members of the GOP indicate that they support a more traditional style of tax reform. The recent failure of President Trump to get a healthcare bill passed also is indicative of how tricky it might be to see an adjusted border tax policy approved by Congress.</li><li>Couple with some recent favorable macroeconomic news, investors are showing some confidence in companies that make and sell clothes.</li> <li>The group of apparel-focused stocks moving higher today include Destination XL Group (<a href='https://seekingalpha.com/symbol/DXLG' title='Destination XL Group, Inc.'>DXLG</a> <font color='green'>+8%</font>), Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a> <font color='green'>+6.7%</font>), Ascena Retail Group (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+6.6%</font>), Stage Stores (<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='green'>+5.7%</font>), J.C. Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='green'>+7.3%</font>), Hibbett Sports (<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a> <font color='green'>+5.1%</font>), Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='green'>+4.3%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='green'>+4%</font>), Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='green'>+3.8%</font>), Land's End (<a href='https://seekingalpha.com/symbol/LE' title='Lands&#39; End, Inc.'>LE</a> <font color='green'>+3.4%</font>), Cherokee (<a href='https://seekingalpha.com/symbol/CHKE' title='Cherokee Inc.'>CHKE</a> <font color='green'>+6.9%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='green'>+4%</font>), G-III Apparel (<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='green'>+6.1%</font>), Oxford Industries (<a href='https://seekingalpha.com/symbol/OXM' title='Oxford Industries Inc.'>OXM</a> <font color='green'>+1.8%</font>), Crocs (<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a> <font color='green'>+3.5%</font>), Fossil (<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+2.1%</font>), Vera Bradely (<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a> <font color='green'>+2%</font>), Sequential Brands Group (<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='green'>+2.2%</font>) &nbsp;and Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='green'>+4.1%</font>).</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3254230\" data-linked=\"Apparel stocks get their day in the sun\" data-tweet=\"$DXLG $DXLG $DDS - Apparel stocks get their day in the sun https://seekingalpha.com/news/3254230-apparel-stocks-get-day-in-sun?source=tweet\" data-url=\"https://seekingalpha.com/news/3254230-apparel-stocks-get-day-in-sun\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254229\" data-ts=\"1490810497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254229-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/MPVD' title='Mountain Province Diamonds, Inc'>MPVD</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254229\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$NADL $ROYT $TRCH - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3254229-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3254229-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254225\" data-ts=\"1490809759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHX\" target=\"_blank\">ATHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254225-william-blairs-initiation-of-athersys-gets-even-wilder-shares-up-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">William Blair&#39;s initiation of Athersys gets even wilder; shares up 25%</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls</a></li><li>\"We view Athersys (<a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='green'>+25.4%</font>) as one of the most asymmetric opportunities in the biotech universe,\" says William Blair. \"Particularly given the clearly defined path to approval.\"</li><li>Noting a pristine safety profile and a SPA agreed upon with the FDA, Blair says should MultiStem hit on its primary endpoint in the MASTERS-2 study, the product will be approved.</li><li>With one of the world's largest markets then opened up with little competitive pressure, Athersys could be a 50x-100x-bagger in the next two years.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254005-william-blair-sees-athersys-nearly-10-bagger-shares-plus-16-percent-post-market\" target=\"_blank\">William Blair sees Athersys as nearly a 10-bagger; shares +16% in post-market</a> (March 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254225\" data-linked=\"William Blair&#39;s initiation of Athersys gets even wilder; shares up 25%\" data-tweet=\"$ATHX - William Blair&#39;s initiation of Athersys gets even wilder; shares up 25% https://seekingalpha.com/news/3254225-william-blairs-initiation-of-athersys-gets-even-wilder-shares-up-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3254225-william-blairs-initiation-of-athersys-gets-even-wilder-shares-up-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254222\" data-ts=\"1490808760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254222-mylans-generic-version-of-gsks-advair-rejected-fda-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mylan&#39;s generic version of GSK&#39;s Advair rejected by FDA; shares down 2%</a></h4><ul><li>Mylan (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-2.2%</font>) has received a complete response letter from the FDA for its abbreviated new drug application for GlaxoSmithKline's (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='green'>+0.6%</font>) Advair Diskus.</li><li>The company<a href=\"https://seekingalpha.com/pr/16784721-mylan-comments-generic-advair-diskus-abbreviated-new-drug-application\" target=\"_blank\"> is in the process</a> of reviewing the CRL.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254222\" data-linked=\"Mylan&#39;s generic version of GSK&#39;s Advair rejected by FDA; shares down 2%\" data-tweet=\"$MYL $MYL $GSK - Mylan&#39;s generic version of GSK&#39;s Advair rejected by FDA; shares down 2% https://seekingalpha.com/news/3254222-mylans-generic-version-of-gsks-advair-rejected-fda-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3254222-mylans-generic-version-of-gsks-advair-rejected-fda-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254254\" data-ts=\"1490808086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NRG\" target=\"_blank\">NRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254254-nrg-energy-raised-to-buy-from-neutral-goldman-sachs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NRG Energy raised to Buy from Neutral at Goldman Sachs</a></h4><ul><li>NRG Energy (<a href='https://seekingalpha.com/symbol/NRG' title='NRG Energy, Inc.'>NRG</a> <font color='green'>+3.5%</font>)&nbsp;is <a href=\"https://www.thestreet.com/story/14064297/1/nrg-energy-stock-upgraded-to-buy-at-goldman-sachs.html\" target=\"_blank\">upgraded to Buy</a> from Neutral with a $26 price target at Goldman Sachs, seeing another 40%-plus upside from current levels even after shares have surged 60% in the past six months.</li><li>Among the reasons for the upgrade, Goldman cites cost management with reductions of ~$180M by 2018  and $250M by 2019, the implementation of a \"shrink and grow\"  strategy aimed at deleveraging, and a potential restructuring of NRG's  GenOn subsidiary.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254254\" data-linked=\"NRG Energy raised to Buy from Neutral at Goldman Sachs\" data-tweet=\"$NRG - NRG Energy raised to Buy from Neutral at Goldman Sachs https://seekingalpha.com/news/3254254-nrg-energy-raised-to-buy-from-neutral-goldman-sachs?source=tweet\" data-url=\"https://seekingalpha.com/news/3254254-nrg-energy-raised-to-buy-from-neutral-goldman-sachs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254215\" data-ts=\"1490807054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254215-buying-picks-up-bit-in-valeant-on-increased-wiggle-room-on-debt-payments-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buying picks up (a bit) in Valeant on increased wiggle room on debt payments; shares ahead 4%</a></h4><ul><li>Valeant Pharmaceuticals (VRX <font color='green'>+4.3%</font>) perks up modestly higher volume as investors move back into the stock as more details emerge on its efforts to secure more favorable debt repayment terms.</li><li>In an <a href=\"https://seekingalpha.com/filing/3477936\" target=\"_blank\">8-K filed today</a>, it reports that it has completed an amendment to its credit revolver extending the maturity date of $1.19B in borrowings to the earlier of April 20, 2020 or 91 days prior to the scheduled maturity of any series or tranche of term loans under its 2012 Credit Agreement, certain unsecured debt and borrowings in excess of $750M. The debt was due on April 20, 2018.</li><li>The company paid a 0.125% fee to lenders execute the change.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254215\" data-linked=\"Buying picks up (a bit) in Valeant on increased wiggle room on debt payments; shares ahead 4%\" data-tweet=\"$BHC - Buying picks up (a bit) in Valeant on increased wiggle room on debt payments; shares ahead 4% https://seekingalpha.com/news/3254215-buying-picks-up-bit-in-valeant-on-increased-wiggle-room-on-debt-payments-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3254215-buying-picks-up-bit-in-valeant-on-increased-wiggle-room-on-debt-payments-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>144&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254214\" data-ts=\"1490806300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTNT\" target=\"_blank\">FTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254214-fortinet-up-4-after-baird-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortinet up 4% after Baird upgrade</a></h4><ul><li>Analyst Jayson Noland sees about&nbsp;<font color='green'>33% upside</font>&nbsp;for the stock, noting the security market has been consolidating, a trend that can be expected to continue, he believes.</li><li>Fortinet (<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a> <font color='green'>+4.3%</font>) had 13.5% of the firewall market last year, says Noland, putting it fourth in line behind Cisco, Palo Alto, and Check Point.</li><li>Noland <a href=\"http://blogs.barrons.com/techtraderdaily/?mod=BOL_hp_blog_tt\" target=\"_blank\">upgrades to Outperform</a> with $50 price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254214\" data-linked=\"Fortinet up 4% after Baird upgrade\" data-tweet=\"$FTNT - Fortinet up 4% after Baird upgrade https://seekingalpha.com/news/3254214-fortinet-up-4-after-baird-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3254214-fortinet-up-4-after-baird-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254213\" data-ts=\"1490806246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254213-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/EXAR' title='Exar Corporation'>EXAR</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/PFMT' title='Performant Financial'>PFMT</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a> <font color='green'>+19%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a>&nbsp;<font color='green'>+14%</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-22%</font>. SSH <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254213\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$TNXP $ATHX $VRTX - Midday Gainers / Losers https://seekingalpha.com/news/3254213-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3254213-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254209\" data-ts=\"1490804933\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254209-webmd-starts-process-of-selling-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WebMD starts process of selling itself, shares up 4%</a></h4><ul><li>Investors sense a deal to acquire WebMD (<a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a> <font color='green'>+4.1%</font>) may be afoot. Shares have perked up in the last hour with volume trending higher. Last month, the company began the process of evaluating strategic options to boost shareholder value.</li><li>Source: <a href=\"http://cnafinance.com/webmd-health-wbmd-stock-spikes-on-sale-process/14501\" target=\"_blank\">CNA Finance</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3244185-webmd-explore-strategic-alternatives-shares-fraction-hours\" target=\"_blank\">WebMD to explore strategic alternatives; shares up a fraction after hours</a> (Feb. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254209\" data-linked=\"WebMD starts process of selling itself, shares up 4%\" data-tweet=\"$WBMD - WebMD starts process of selling itself, shares up 4% https://seekingalpha.com/news/3254209-webmd-starts-process-of-selling-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3254209-webmd-starts-process-of-selling-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254207\" data-ts=\"1490804639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254207-webmd-reportedly-starts-sale-process-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WebMD reportedly starts sale process; up 5%</a></h4><ul><li>According to dealReporter, the company has reached out to potential buyers, with a hoped-for price in the 12x-13x EBITDA range.</li><li><a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a>&nbsp;<font color='green'>+5%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3254207\" data-linked=\"WebMD reportedly starts sale process; up 5%\" data-tweet=\"$WBMD - WebMD reportedly starts sale process; up 5% https://seekingalpha.com/news/3254207-webmd-reportedly-starts-sale-process-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3254207-webmd-reportedly-starts-sale-process-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254205\" data-ts=\"1490803216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254205-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SYPR' title='Sypris Solutions, Inc.'>SYPR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/THST' title='Truett-Hurst, Inc.'>THST</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SANW' title='S&W Seed Co'>SANW</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254205\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$XELB $WKHS $SYPR - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3254205-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3254205-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254203\" data-ts=\"1490803058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEDL\" target=\"_blank\">VEDL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254203-vedantas-agarwal-says-no-plans-to-buy-anglo-american-assets-in-south-africa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vedanta&#39;s Agarwal says no plans to buy Anglo American assets in South Africa</a></h4><ul>     <li>Vedanta (<a href='https://seekingalpha.com/symbol/VEDL' title='Vedanta Ltd'>VEDL</a> <font color='green'>+1.5%</font>) Chairman Anil Agarwal says he had <a href=\"http://www.reuters.com/article/vedanta-anglo-american-idUSL5N1H61QW\" target=\"_blank\">no plans to buy assets</a> in South Africa from Anglo American (<a href='https://seekingalpha.com/symbol/AAUKF' title='Anglo American plc'>OTCQX:AAUKF</a>, <a href='https://seekingalpha.com/symbol/AAUKY' title='Anglo American plc ADR'>OTCPK:AAUKY</a>) or push for a board seat, two weeks after announcing plans to <a href=\"https://seekingalpha.com/news/3251527-indian-billionaire-agarwal-buy-2_4b-stake-anglo-american\" target=\"_blank\">buy a 13% stake</a> in the miner.</li>     <li>Agarwal said this month that he would buy a stake of as much as 2B in Anglo but through his family trust rather than VEDL.</li>     <li>\"I believe in the management, I believe in the company... I am not an activist,\" Agarwal says of his potential role as an Anglo shareholder, and says he has \"no agenda\" to seek a board position.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254203\" data-linked=\"Vedanta&#39;s Agarwal says no plans to buy Anglo American assets in South Africa\" data-tweet=\"$VEDL $VEDL $AAUKF - Vedanta&#39;s Agarwal says no plans to buy Anglo American assets in South Africa https://seekingalpha.com/news/3254203-vedantas-agarwal-says-no-plans-to-buy-anglo-american-assets-in-south-africa?source=tweet\" data-url=\"https://seekingalpha.com/news/3254203-vedantas-agarwal-says-no-plans-to-buy-anglo-american-assets-in-south-africa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254201\" data-ts=\"1490802936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254201-pulmatrix-perks-up-8-on-rumored-mylan-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix perks up 8% on rumored Mylan interest</a></h4><ul><li>Nano cap Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+7.5%</font>) shows some life on rumored interest by collaboration partner Mylan N.V. (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-0.8%</font>) in a takeover bid.</li><li>Mylan had an option on the ex-U.S. rights to COPD candidate PUR0200 but did not exercise it.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2583865-pulmatrix-inks-development-deal-with-mylan\" target=\"_blank\">Pulmatrix inks development deal with Mylan</a> (June 16, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254201\" data-linked=\"Pulmatrix perks up 8% on rumored Mylan interest\" data-tweet=\"$PULM $PULM $MYL - Pulmatrix perks up 8% on rumored Mylan interest https://seekingalpha.com/news/3254201-pulmatrix-perks-up-8-on-rumored-mylan-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3254201-pulmatrix-perks-up-8-on-rumored-mylan-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254198\" data-ts=\"1490802415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEGYF\" target=\"_blank\">GEGYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254198-reuters-genel-energy-cfo-to-step-down-chairman-search-continues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Genel Energy CFO to step down, as chairman search continues</a></h4><ul>     <li>Genel Energy (<a href='https://seekingalpha.com/symbol/GEGYF' title='Genel Energy PLC'>OTCPK:GEGYF</a> <font color='red'>-4.4%</font>) is bracing for the <a href=\"http://www.reuters.com/article/us-genel-energy-cfo-idUSKBN17023P\" target=\"_blank\">departure of its CFO</a> while still struggling to find a replacement for Chairman Tony Hayward, who plans to step down in June, Reuters reports.</li>     <li>CFO Ben Monaghan, a former senior banker who joined Genel in 2015, is expected to leave after Hayward's departure but before the end of the year, according to the report.</li>     <li>Genel's market value already had collapsed to a record low <a href=\"https://seekingalpha.com/news/3253913-genel-energy-cuts-reserves-estimate-key-field\" target=\"_blank\">yesterday</a> after announcing a second downward revision of reserves at the company's flagship Taq Taq field in Kurdistan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254198\" data-linked=\"Reuters: Genel Energy CFO to step down, as chairman search continues\" data-tweet=\"$GEGYF - Reuters: Genel Energy CFO to step down, as chairman search continues https://seekingalpha.com/news/3254198-reuters-genel-energy-cfo-to-step-down-chairman-search-continues?source=tweet\" data-url=\"https://seekingalpha.com/news/3254198-reuters-genel-energy-cfo-to-step-down-chairman-search-continues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254193\" data-ts=\"1490801475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SO\" target=\"_blank\">SO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254193-southern-co-ceo-to-ask-toshiba-to-help-complete-georgia-reactors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southern Co. CEO to ask Toshiba to help complete Georgia reactors</a></h4><ul>     <li>Southern Co. (<a href='https://seekingalpha.com/symbol/SO' title='Southern Company'>SO</a>) CEO Tom Fanning says he will ask&nbsp;Toshiba (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a> <font color='red'>-1.5%</font>) to honor what he says is a commitment to <a href=\"https://www.wsj.com/articles/southern-co-ceo-says-will-ask-toshiba-to-help-complete-georgia-reactors-1490794563\" target=\"_blank\">complete two nuclear reactors</a> in Georgia after lead contractor Westinghouse <a href=\"https://seekingalpha.com/news/3254029-toshiba-approves-westinghouse-bankruptcy\" target=\"_blank\">filed for bankruptcy protection</a>.</li>     <li>Ahead of talks with Toshiba and Japanese government officials today, Fanning tells <em>WSJ</em> that the Vogtle project has the support of the U.S. administration as a direct employer of 5K people and a creator of 30K jobs throughout the supply chain.</li>     <li>&ldquo;The commitments are not just financial and operational, but there are moral commitments as well,&rdquo; Fanning says.</li>     <li>Toshiba and its creditors likely will see it differently: Toshiba says it will honor ~&yen;650B ($5.9B) in Westinghouse obligations it had guaranteed, but that it plans to exit the business of building nuclear plants and does not expect further losses.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254193\" data-linked=\"Southern Co. CEO to ask Toshiba to help complete Georgia reactors\" data-tweet=\"$SO $SO $TOSBF - Southern Co. CEO to ask Toshiba to help complete Georgia reactors https://seekingalpha.com/news/3254193-southern-co-ceo-to-ask-toshiba-to-help-complete-georgia-reactors?source=tweet\" data-url=\"https://seekingalpha.com/news/3254193-southern-co-ceo-to-ask-toshiba-to-help-complete-georgia-reactors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254191\" data-ts=\"1490801057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PACB\" target=\"_blank\">PACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254191-cowen-bullish-on-growth-of-next-gen-sequencing-says-pac-bios-systems-best-for-small-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen bullish on growth of next-gen sequencing, says Pac Bio&#39;s systems best for small volume work, shares ahead 12%</a></h4><ul><li>Pacific Biosciences of California (<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a> <font color='green'>+12.4%</font>) perks up on more than a 60% spike in volume. Earlier today, Cowen and Company released the results of a 51-lab survey revealing a bullish environment for next-generation sequencing demand, possibly up 80% this year.</li><li>Cowen says PACB's sequencing franchise is \"making steady improvements\" and generating more interest. It adds that the company's gear is best for small volume work with \"confidence building.\" Sequencing an entire genome for $1,000 should be attainable on a PACB system by the end of next year.</li><li>Source: Bloomberg</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/QGEN' title='Qiagen N.V.'>QGEN</a> <font color='red'>-1%</font>)(<a href='https://seekingalpha.com/symbol/TMO' title='Thermo Fisher Scientific Inc.'>TMO</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies'>NSTG</a> <font color='red'>-0.1%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254191\" data-linked=\"Cowen bullish on growth of next-gen sequencing, says Pac Bio&#39;s systems best for small volume work, shares ahead 12%\" data-tweet=\"$PACB $PACB $ILMN - Cowen bullish on growth of next-gen sequencing, says Pac Bio&#39;s systems best for small volume work, shares ahead 12% https://seekingalpha.com/news/3254191-cowen-bullish-on-growth-of-next-gen-sequencing-says-pac-bios-systems-best-for-small-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3254191-cowen-bullish-on-growth-of-next-gen-sequencing-says-pac-bios-systems-best-for-small-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254188\" data-ts=\"1490799752\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254188-nutanix-lockup-expiration-presses-sharesminus-7_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix lockup expiration presses shares, -7.6%</a></h4><ul>   <li>Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) is <font color='red'>7.6% lower</font> with the arrival of a six-month post-IPO lockup expiration, allowing employees to sell a large chunk of outstanding shares, and volume has already quadrupled the stock's daily average in the first 90 minutes of trading.</li>    <li>After hitting a high of $46.78 in its first few days of trading in October, the stock has now <font color='red'>slid 61% </font>since, to $18.42 (but still 15% above IPO price).</li>    <li>Meanwhile, the shares look cheap to Piper Jaffray with the lockup expiration creating an opportunity. The current valuation is \"compelling\" even with selling pressure, with the company's enterprise value to 2018 sales multiple around 1.9 times, vs. peers' 3.7 times.</li><li>Analyst Andrew Nowinski has an Overweight rating and $36 price target, implying 95% upside from today's depressed level.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254188\" data-linked=\"Nutanix lockup expiration presses shares, -7.6%\" data-tweet=\"$NTNX - Nutanix lockup expiration presses shares, -7.6% https://seekingalpha.com/news/3254188-nutanix-lockup-expiration-presses-sharesminus-7_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3254188-nutanix-lockup-expiration-presses-sharesminus-7_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254158\" data-ts=\"1490799608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254158-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/NYMX' title='Nymox Pharmaceutical Corporation'>NYMX</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-18%</font>. SSH <font color='red'>-17%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254158\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$TNXP $NYMX $VRTX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3254158-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3254158-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254182\" data-ts=\"1490799419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LL\" target=\"_blank\">LL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254182-lumber-liquidatorsplus-7-after-positive-home-sales-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumber Liquidators +7% after positive home sales data</a></h4><ul> <li>Lumber Liquidators (NYSE:<a href='https://seekingalpha.com/symbol/LL' title='Lumber Liquidators Holdings, Inc.'>LL</a>) is <font color='green'>up 6.71%</font> on strong early volume.</li> <li>A positive report</a> from the National Association of Realtors on pending home sales could be bringing in some buyers.</li> <li>\"Buyers came back in force last month as a modest, seasonal uptick in listings were enough to fuel an increase in contract signings throughout the country,\" notes NAR chief economist Lawrence Yun.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254161-pending-home-sales-pop-february\" target=\"_blank\">Pending home sales pop in February</a> (March 29)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3254182\" data-linked=\"Lumber Liquidators +7% after positive home sales data\" data-tweet=\"$LL - Lumber Liquidators +7% after positive home sales data https://seekingalpha.com/news/3254182-lumber-liquidatorsplus-7-after-positive-home-sales-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3254182-lumber-liquidatorsplus-7-after-positive-home-sales-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254181\" data-ts=\"1490799156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRS\" target=\"_blank\">BRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254181-bristowplus-8-presenting-energy-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristow +8% presenting at energy conference</a></h4><ul><li>Expects challenging market conditions and offshore E&amp;P spend to be down again in FY18, but \"green shoots are beginning to appear.\"</li><li>Leased aircraft will offset rent savings from returned aircraft in the short term.</li><li>Improving liquidity runway by $630M.  Continues to reduce incremental lease costs.</li><li>Employing aviation competencies to diversify complementary and growing businesses.</li><li>Notes successful execution of FY17 Action Plan and recent tenders as evidence the company can maintain its leadership position.</li><li><a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a> shares are <font color='green'>up almost 8%</font> on the news.</li><li>See full presentation <a href=\"https://www.sec.gov/Archives/edgar/data/73887/000119312517100840/d363836dex991.htm\" target=\"_blank\">here</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3254181\" data-linked=\"Bristow +8% presenting at energy conference\" data-tweet=\"$BRS - Bristow +8% presenting at energy conference https://seekingalpha.com/news/3254181-bristowplus-8-presenting-energy-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/3254181-bristowplus-8-presenting-energy-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254180\" data-ts=\"1490799076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254180-under-armour-heads-higher-amid-trader-chatter-of-pe-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour heads higher amid trader chatter of PE deal</a></h4><ul> <li>Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>, <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) breaks higher amid some trader chatter of a coming private equity deal. There's nothing concrete about the speculation, but it's been enough to push up morning trading volume.</li> <li>UA <font color='green'>+1.95%</font>. UAA <font color='green'>+3.52%</font>.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3254180\" data-linked=\"Under Armour heads higher amid trader chatter of PE deal\" data-tweet=\"$UA $UA $UAA - Under Armour heads higher amid trader chatter of PE deal https://seekingalpha.com/news/3254180-under-armour-heads-higher-amid-trader-chatter-of-pe-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3254180-under-armour-heads-higher-amid-trader-chatter-of-pe-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254179\" data-ts=\"1490798911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254179-cymabay-chief-retires-cfo-named-interim-successor-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay chief retires, CFO named as interim successor; shares ahead 2%</a></h4><ul><li>CymaBay Therapeutics (<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a> <font color='green'>+2%</font>) President &amp; CEO Harold Van Wart, Ph.D., <a href=\"https://seekingalpha.com/pr/16784015-cymabay-announces-retirement-president-chief-executive-officer-harold-van-wart-ph-d\" target=\"_blank\">announces</a> his retirement. The board has promoted CFO Sujal Shah to succeed him on an interim basis. Robert Wills, Ph.D., will assume the role of Executive Chairman to help with the transition.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254179\" data-linked=\"CymaBay chief retires, CFO named as interim successor; shares ahead 2%\" data-tweet=\"$CBAY - CymaBay chief retires, CFO named as interim successor; shares ahead 2% https://seekingalpha.com/news/3254179-cymabay-chief-retires-cfo-named-interim-successor-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3254179-cymabay-chief-retires-cfo-named-interim-successor-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254175\" data-ts=\"1490798403\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSW\" target=\"_blank\">INSW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254175-post-earnings-slide-for-international-seaways\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings slide for International Seaways</a></h4><ul> <li>International Seaways (<a href='https://seekingalpha.com/symbol/INSW' title='International Seaways'>INSW</a> <font color='red'>-7.4%</font>) swings lower after reporting time charter revenue fell 31% to $82M in Q4.</li> <li>The company's net loss for the quarter widened to $57.8M. Adjusted EBITDA was down 47% to $37.5M.</li> <li>\"While we expect the year ahead to present a number of challenges, I am confident in the solid foundation we have built and the measures we continue to take to create a platform for success,\" says CEO Lois Zabrocky.</li> <li>Shares of International Seaways are still up 35% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254175\" data-linked=\"Post-earnings slide for International Seaways\" data-tweet=\"$INSW - Post-earnings slide for International Seaways https://seekingalpha.com/news/3254175-post-earnings-slide-for-international-seaways?source=tweet\" data-url=\"https://seekingalpha.com/news/3254175-post-earnings-slide-for-international-seaways\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254170\" data-ts=\"1490797873\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254170-crude-futures-jump-after-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures jump after inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a>&nbsp;Crude <strong>+0.9M </strong>barrels vs. +1.36M consensus, +5.0M last week.</li><li>Gasoline <strong>-3.7M</strong> barrels vs. -1.89M consensus, -2.8M last week.</li><li>Distillates <strong>-2.5M</strong> vs. -1.23M consensus, -1.9M last week.</li><li>Futures&nbsp;<font color='green'>+0.97%</font>&nbsp;to $48.84.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3254170\" data-linked=\"Crude futures jump after inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures jump after inventory data https://seekingalpha.com/news/3254170-crude-futures-jump-after-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3254170-crude-futures-jump-after-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254165\" data-ts=\"1490797034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254165-dryships-gains-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips gains again</a></h4><ul> <li>DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>) is <font color='green'>up 14%</font> to extend on yesterday's gain amid a broad rally in dry bulk shippers.</li> <li>The company has been adding more vessels to its fleet this year with spot rates showing some improvement.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3253528-dryships-acquires-four-modern-newcastlemax-vessels\" target=\"_blank\">Dryships acquires four modern Newcastlemax vessels</a> (March 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253892-rally-time-shipping-stocks\" target=\"_blank\">Rally time for shipping stocks</a> (March 28)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3254165\" data-linked=\"DryShips gains again\" data-tweet=\"$DRYS - DryShips gains again https://seekingalpha.com/news/3254165-dryships-gains-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3254165-dryships-gains-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254162\" data-ts=\"1490796375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INNL\" target=\"_blank\">INNL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254162-innocoll-clarifies-data-needed-to-support-refiling-of-u-s-marketing-application-for-xaracoll\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innocoll clarifies data needed to support refiling of U.S. marketing application for XARACOLL, resubmission possible by year-end; shares ahead 34%</a></h4><ul><li>Innocoll Holdings (<a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a> <font color='green'>+34.3%</font>) jumps on triple normal volume in response to its <a href=\"https://seekingalpha.com/pr/16784376-innocoll-announces-regulatory-path-forward-receiving-formal-fda-type-meeting-minutes\" target=\"_blank\">announcement </a>of a clear regulatory path to resubmitting its New Drug Application &#40;NDA&#41; with the FDA seeking approval of XARACOLL (bupivacaine HCl collagen-matrix implant) for the treatment of postsurgical pain. The company received a Refusal to File &#40;RTF&#41; letter in December 2016 in response to its initial submission. An RTF means that the filing is not complete enough to review.</li><li>Minutes from the Type A meeting specified the following requirements for an acceptable NDA: an additional short-term pharmacokinetic study, several short-term nonclinical toxicology and biocompatibility studies, additional manufacturing information to address the new combination product designation and other chemistry, manufacturing and control &#40;CMC&#41; information.</li><li>The company believes that it can complete the work and refile the NDA by the end of the year if it has the necessary funding.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3232836-innocoll-gets-refusal-file-letter-fda-xaracoll-minus-52-percent-hours\" target=\"_blank\">Innocoll gets refusal to file letter from FDA on XARACOLL; -52% after hours</a> (Dec. 29, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254162\" data-linked=\"Innocoll clarifies data needed to support refiling of U.S. marketing application for XARACOLL, resubmission possible by year-end; shares ahead 34%\" data-tweet=\"$INNL - Innocoll clarifies data needed to support refiling of U.S. marketing application for XARACOLL, resubmission possible by year-end; shares ahead 34% https://seekingalpha.com/news/3254162-innocoll-clarifies-data-needed-to-support-refiling-of-u-s-marketing-application-for-xaracoll?source=tweet\" data-url=\"https://seekingalpha.com/news/3254162-innocoll-clarifies-data-needed-to-support-refiling-of-u-s-marketing-application-for-xaracoll\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254153\" data-ts=\"1490795382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INPX\" target=\"_blank\">INPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254153-inpixonplus-9_7-on-army-contract-extension\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inpixon +9.7% on Army contract extension</a></h4><ul>   <li>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) is <font color='green'>up 9.7%</font> as the U.S. Army has <a href=\"https://seekingalpha.com/pr/16784394-u-s-army-extends-contract-inpixon\" target=\"_blank\">extended a contract</a> with the firm.</li>    <li>The Army Contracting Command &ndash; Rock Island Munitions Transportation Management System was renewed for a second ordering period.</li>    <li>The company's sensors are made to find all accessible cellular, Wi-Fi, and Bluetooth devices anonymously. It holds a number of other federal contract vehicles.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254153\" data-linked=\"Inpixon +9.7% on Army contract extension\" data-tweet=\"$INPX - Inpixon +9.7% on Army contract extension https://seekingalpha.com/news/3254153-inpixonplus-9_7-on-army-contract-extension?source=tweet\" data-url=\"https://seekingalpha.com/news/3254153-inpixonplus-9_7-on-army-contract-extension\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254147\" data-ts=\"1490794713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUNW\" target=\"_blank\">SUNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254147-sunworksplus-5-q4-revenue-beat-record-backlog\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunworks +5% with Q4 revenue beat, record backlog</a></h4><ul>    <li>Sunworks (NASDAQ:<a href='https://seekingalpha.com/symbol/SUNW' title='Sunworks, Inc.'>SUNW</a>) has come out of the open <font color='green'>up 5.1%</font> following <a href=\"https://seekingalpha.com/news/3254055-sunworks-beats-revenue\" target=\"_blank\">Q4 earnings</a> where it edged revenue expectations and replaced its chief executive.</li>    <li>The company <a href=\"https://seekingalpha.com/pr/16783927-sunworks-appoints-charles-f-cargile-chief-executive-officer\" target=\"_blank\">named Charles Cargile its CEO</a>, replacing James Nelson, who will continue on as chairman of the board.</li>    <li>The company swung to a loss but built a record backlog coming into the new fiscal year. It experienced rainy weather during a normally busy Q4, Nelson said.</li>    <li>In addition, some losses were noncash adjustments the company does not expect to recur this year.</li>    <li>Order backlog stood at $48.5M (up 2% Y/Y). The backlog amounted to 15.8 megawatts in orders.</li>    <li>The company is forecasting a profit for the full year with revenues increasing more than 30%; it expects higher backlog both Y/Y and sequentially at the end of Q1.</li>    <li><a href=\"http://ir.sunworksusa.com/\" target=\"_blank\">Conference call</a> to come at 10 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16783913-sunworks-reports-fourth-quarter-full-year-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3254147\" data-linked=\"Sunworks +5% with Q4 revenue beat, record backlog\" data-tweet=\"$SUNW - Sunworks +5% with Q4 revenue beat, record backlog https://seekingalpha.com/news/3254147-sunworksplus-5-q4-revenue-beat-record-backlog?source=tweet\" data-url=\"https://seekingalpha.com/news/3254147-sunworksplus-5-q4-revenue-beat-record-backlog\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254135\" data-ts=\"1490793714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254135-sangamos-zfp-tf-gene-regulating-technology-shows-significant-effect-on-tau-expression-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo&#39;s ZFP-TF gene regulating technology shows significant effect on tau expression in preclinical testing; shares up 12% premarket</a></h4><ul><li>Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) heads north&nbsp;<font color='green'>12%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16783944-sangamo-therapeutics-announces-presentation-new-data-demonstrating-significant-reduction-tau\" target=\"_blank\">announcement </a>of encouraging preclinical data related to its zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation technology.</li><li>In animal model testing, ZFP-TF showed a significant reduction in tau mRNA and tau protein expression, the first evidence of a tau-lowering agent showing efficacy on neuritic dystrophy in an amyloid mouse model of Alzheimer's disease &#40;AD&#41;. The data were presented at the 13th International Conference on Alzheimer's &amp; Parkinson's Diseases in Vienna, Austria.</li><li>Lowering tau protein is currently the \"big hope\" in treating AD since the amyloid plaque approach has failed to bear fruit.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254135\" data-linked=\"Sangamo&#39;s ZFP-TF gene regulating technology shows significant effect on tau expression in preclinical testing; shares up 12% premarket\" data-tweet=\"$SGMO - Sangamo&#39;s ZFP-TF gene regulating technology shows significant effect on tau expression in preclinical testing; shares up 12% premarket https://seekingalpha.com/news/3254135-sangamos-zfp-tf-gene-regulating-technology-shows-significant-effect-on-tau-expression-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3254135-sangamos-zfp-tf-gene-regulating-technology-shows-significant-effect-on-tau-expression-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254134\" data-ts=\"1490793604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254134-rh-earnings-send-shorts-scrambling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RH earnings send shorts scrambling</a></h4><ul> <li>Shares of Restoration Hardware (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>) soar after the company does enough with its Q4 report to send shorts scrambling (39% short interest into the report).</li> <li>On Wall Street, Loop Capital says it remains unconvinced and Piper Jaffray (Neutral, $43 PT) is fretting over RH's inventory level - but Guggenheim (Buy, $55 PT) thinks the worst is now behind the retailer and sees \"significant\" value creation over the next three to five years.</li> <li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253972-rh-beats-0_03-beats-revenue\" target=\"_blank\">RH beats by $0.03, beats on revenue</a> (March 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254019-rh-jumps-15_9-percent-q4-beat-robust-revenue-guidance\" target=\"_blank\">RH jumps 15.9% on Q4 beat, robust revenue guidance</a> (March 28)</li> <li>RH <font color='green'>+16.53%</font> premarket to $44.28 vs. a 52-week trading range of $24.41 to $46.87.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254134\" data-linked=\"RH earnings send shorts scrambling\" data-tweet=\"$RH - RH earnings send shorts scrambling https://seekingalpha.com/news/3254134-rh-earnings-send-shorts-scrambling?source=tweet\" data-url=\"https://seekingalpha.com/news/3254134-rh-earnings-send-shorts-scrambling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254137\" data-ts=\"1490793507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROYT\" target=\"_blank\">ROYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254137-pacific-coast-oil-trustplus-6-after-distribution-hike-stifel-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Coast Oil Trust +6% after distribution hike, Stifel upgrade</a></h4><ul><li>Pacific Coast Oil Trust (NYSE:<a href='https://seekingalpha.com/symbol/ROYT' title='Pacific Coast Oil Trust'>ROYT</a>)&nbsp;<font color='green'>+6.2%</font> premarket following its announcement late yesterday that it was <a href=\"https://seekingalpha.com/news/3254000-pacific-coast-oil-trust-declares-0_02617-dividend\" target=\"_blank\">raising its April cash distribution</a> to $0.02617/unit from $0.00487.</li><li>Stifel <a href=\"https://www.streetinsider.com/Analyst+EPS+Change/UPDATE%3A+Stifel+Upgrades+Pacific+Coast+Oil+Trust+%28ROYT%29+to+Buy+Citing+Valuation/12716724.html\" target=\"_blank\">upgrades</a> ROYT to Buy from Hold with a $2 price target following the news, noting that while production fell slightly, the trust  said it would exceed $2M of proceeds in 2017 and thus would not be at risk of dissolution at year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254137\" data-linked=\"Pacific Coast Oil Trust +6% after distribution hike, Stifel upgrade\" data-tweet=\"$ROYT - Pacific Coast Oil Trust +6% after distribution hike, Stifel upgrade https://seekingalpha.com/news/3254137-pacific-coast-oil-trustplus-6-after-distribution-hike-stifel-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3254137-pacific-coast-oil-trustplus-6-after-distribution-hike-stifel-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254131\" data-ts=\"1490793430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254131-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a> <font color='red'>-28%</font>&nbsp;on equity offering.</li><li>SSH <font color='red'>-15%</font>.</li><li><a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='red'>-11%</font>&nbsp;on securing a new patent.</li><li><a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='red'>-9%</font>.</li><li><a href='https://seekingalpha.com/symbol/SKX' title='Skechers USA Inc.'>SKX</a> <font color='red'>-6%</font>&nbsp;on Susquehanna sales rating.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3254131\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$ATOS $CHFS $DFFN - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3254131-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3254131-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254132\" data-ts=\"1490793387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254132-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+65%</font> on start of Phase 3 clinical trial of TNX-102 SL in PTSD.</li><li><a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+23%</font> on approval of IND for hemophilia B candidate CB 2679d/ISU304 by Korean Ministry of Food and Drug Safety. </li><li><a href='https://seekingalpha.com/symbol/SNOA' title='Sonoma Pharmaceuticals, Inc.'>SNOA</a> <font color='green'>+22%</font> on clearance from the FDA for its Loyon Skin Descaler.</li><li><a href='https://seekingalpha.com/symbol/EXAR' title='Exar Corporation'>EXAR</a> <font color='green'>+22%</font>on being acquired by MaxLinear for $13/share.<br></li><li><a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+21%</font> on  positive results from  two Phase 3 clinical trials assessing the combination of tezacaftor and  ivacaftor in patients with cystic fibrosis.</li><li><a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='green'>+18%</font> after receiving $11 price target by William Blair.</li><li><a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+16%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='green'>+13%</font> on presentation of new data demonstrating significant reduction of tau mRNA and tau protein  expression using the company's zinc finger protein transcription factor technology.</li><li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+11%</font>.</li><li><a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+9%</font> after Morgan Stanley upgrade of dry bulk stocks.<br></li><li><a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3254132\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$TNXP $CBIO $SNOA - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3254132-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3254132-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254130\" data-ts=\"1490792961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COWN\" target=\"_blank\">COWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254130-cowen-sells-20-stake-to-cefc-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen sells 20% stake to CEFC China</a></h4><ul> <li>Shares of Cowen (NASDAQ:<a href='https://seekingalpha.com/symbol/COWN' title='Cowen Group, Inc.'>COWN</a>) jump after the company <a href=\"http://www.cowen.com/investor-relations/news/\" target=\"_blank\">announces</a> a strategic partnership with CEFC China.</li> <li>CEFC takes a 19.9% stake in Cowen for ~$100M and is providing the financial services firm with $175M in debt financing. The new class A shares picked up by CEFC will be bought at $18 per share.</li> <li>CEFC will appoint three members to the board at Cowen as part of the deal.</li> <li>COWN <font color='green'>+17.27%</font> premarket to $16.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254130\" data-linked=\"Cowen sells 20% stake to CEFC China\" data-tweet=\"$COWN - Cowen sells 20% stake to CEFC China https://seekingalpha.com/news/3254130-cowen-sells-20-stake-to-cefc-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3254130-cowen-sells-20-stake-to-cefc-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254129\" data-ts=\"1490792628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254129-tonix-up-big-on-start-of-late-stage-study-of-tnxminus-102-sl-shares-ahead-66-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix up big on start of late-stage study of TNX-102 SL; shares ahead 66% premarket</a></h4><ul><li>Investors are downright giddy over Tonix Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) start of a Phase 3 clinical trial assessing TNX-102 SL in PTSD. Shares are up&nbsp;<font color='green'>66%&nbsp;</font>premarket on robust volume.</li><li>The study is expected to wind up in October 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253934-enrollment-underway-tonix-pharmas-late-stage-study-tnxminus-102-ptsd\" target=\"_blank\">Enrollment underway in Tonix Pharma's late-stage study of TNX-102 in PTSD</a> (March 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254129\" data-linked=\"Tonix up big on start of late-stage study of TNX-102 SL; shares ahead 66% premarket\" data-tweet=\"$TNXP - Tonix up big on start of late-stage study of TNX-102 SL; shares ahead 66% premarket https://seekingalpha.com/news/3254129-tonix-up-big-on-start-of-late-stage-study-of-tnxminus-102-sl-shares-ahead-66-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3254129-tonix-up-big-on-start-of-late-stage-study-of-tnxminus-102-sl-shares-ahead-66-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254125\" data-ts=\"1490792270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254125-blueprint-med-readies-equity-offering-shares-ease-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blueprint Med readies equity offering; shares ease 3% premarket</a></h4><ul><li>Blueprint Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>) slips&nbsp;<font color='red'>3%</font>&nbsp;premarket, albeit on only 50 shares, in response to its <a href=\"https://seekingalpha.com/pr/16783951-blueprint-medicines-announces-proposed-public-offering-shares-common-stock\" target=\"_blank\">announcement </a>of a $150M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254125\" data-linked=\"Blueprint Med readies equity offering; shares ease 3% premarket\" data-tweet=\"$BPMC - Blueprint Med readies equity offering; shares ease 3% premarket https://seekingalpha.com/news/3254125-blueprint-med-readies-equity-offering-shares-ease-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3254125-blueprint-med-readies-equity-offering-shares-ease-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254121\" data-ts=\"1490792090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUN\" target=\"_blank\">HUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254121-huntsman-reaffirms-merger-options-sending-shares-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huntsman reaffirms merger options, sending shares higher</a></h4><ul>     <li>Huntsman (NYSE:<a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a>) <font color='green'>+2.6%</font> premarket and set to add to yesterday's 5.3% gain after Chairman Jon Huntsman Sr. said in an interview  with Bloomberg that the company is \"looking seriously at the possibility of doing a merger or doing something that would double or triple\" its revenues.</li>     <li>In a <a href=\"https://seekingalpha.com/pr/16783866-huntsman-reconfirms-options-following-separation-create-shareholder-value\" target=\"_blank\">statement</a> today, HUN says the chairman's remarks were consistent with statements previously made by CEO Peter Huntsman, who has said the company \"has numerous options to increase  shareholder value following the separation [of its pigments and additives business], including a merger of equals transaction.\"</li>     <li>Sentiment also was bullish yesterday after HUN <a href=\"https://seekingalpha.com/news/3253717-huntsman-sees-q1-adjusted-ebitda-rising-year-ago\" target=\"_blank\">guided</a> for Q1 adjusted EBITDA above the $274M tallied in the year-ago  quarter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254121\" data-linked=\"Huntsman reaffirms merger options, sending shares higher\" data-tweet=\"$HUN - Huntsman reaffirms merger options, sending shares higher https://seekingalpha.com/news/3254121-huntsman-reaffirms-merger-options-sending-shares-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3254121-huntsman-reaffirms-merger-options-sending-shares-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254120\" data-ts=\"1490792040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALQA\" target=\"_blank\">ALQA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254120-alliqua-bio-prices-equity-offering-shares-slump-34-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alliqua Bio prices equity offering; shares slump 34% premarket</a></h4><ul><li>Penny stock Alliqua BioMedical (NASDAQ:<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a>) plummets&nbsp;<font color='red'>34%</font>&nbsp;premarket on robust volume in response to the <a href=\"https://seekingalpha.com/pr/16783953-alliqua-biomedical-inc-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing </a>of its public offering of 9.375M shares of common stock at $0.40. Closing date is April 3.</li><li>Yesterday's close was $0.6252.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254120\" data-linked=\"Alliqua Bio prices equity offering; shares slump 34% premarket\" data-tweet=\"$ALQA $ADYX - Alliqua Bio prices equity offering; shares slump 34% premarket https://seekingalpha.com/news/3254120-alliqua-bio-prices-equity-offering-shares-slump-34-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3254120-alliqua-bio-prices-equity-offering-shares-slump-34-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254117\" data-ts=\"1490791785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTTR\" target=\"_blank\">RTTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254117-ritter-pharmas-lactose-intolerance-candidate-rp-g28-shows-positive-effect-in-mid-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ritter Pharma&#39;s lactose intolerance candidate RP-G28 shows positive effect in mid-stage study but only after excluding bad data; shares down 7% premarket</a></h4><ul><li>Results from a Phase 2b/3 clinical trial assessing Ritter Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a>) RP-G28 in people with lactose intolerance showed an <a href=\"https://seekingalpha.com/pr/16783701-ritter-pharmaceuticals-announces-lactose-intolerance-treatment-rp-g28-demonstrated-efficacy\" target=\"_blank\">encouraging treatment benefit</a>, evidenced by a reduction in symptoms across a range of outcome measures, but only after excluding data from one center.</li><li>The 377-subject Phase 2b stage met its primary endpoint showed a statistically significantly larger responder group (40%) who received RP-G28 compared to placebo (26%) (p=0.0159). The difference in the number of responders in the high-dose group versus placebo was also statistically significant (p=0.0294) as was the low-dose group (p=0.0434).</li><li>The primary analysis (n=296) excluded one trial site due to \"significant irregularities.\"</li><li>The results from the entire study population (n=368), including the rogue site, fell short of statistical significance (p=0.0618).</li><li>The company plans to meet with the FDA in an End-of-Phase 2 meeting during which it expects to clarify the design of a confirmatory Phase 3 study.</li><li><a href=\"http://www.ritterpharmaceuticals.com/product-platform/rpg28\" target=\"_blank\">RP-G28</a>,&nbsp;a highly purified&nbsp;<a href=\"http://en.wikipedia.org/wiki/Galactooligosaccharide\" target=\"_blank\">galactooligosaccharide</a>,&nbsp;is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. If approved, it will be the first drug cleared by the FDA for the indication.</li><li>Shares are down&nbsp;<font color='red'>7%&nbsp;</font>premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254117\" data-linked=\"Ritter Pharma&#39;s lactose intolerance candidate RP-G28 shows positive effect in mid-stage study but only after excluding bad data; shares down 7% premarket\" data-tweet=\"$RTTR - Ritter Pharma&#39;s lactose intolerance candidate RP-G28 shows positive effect in mid-stage study but only after excluding bad data; shares down 7% premarket https://seekingalpha.com/news/3254117-ritter-pharmas-lactose-intolerance-candidate-rp-g28-shows-positive-effect-in-mid-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3254117-ritter-pharmas-lactose-intolerance-candidate-rp-g28-shows-positive-effect-in-mid-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254111\" data-ts=\"1490790794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CC\" target=\"_blank\">CC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254111-chemours-upgraded-to-buy-jefferies-on-additional-cyclical-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chemours upgraded to Buy at Jefferies on additional cyclical upside</a></h4><ul><li>Chemours (NYSE:<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a>) <font color='green'>+2.8%</font> premarket after Jefferies <a href=\"https://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Chemours+%28CC%29+to+Buy%3B+Cyclical+Upside+Remains/12717323.html\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $48 price target, raised from $35, saying the stock still has significant  &ldquo;cyclical upside\" and the company has more &ldquo;self-help&rdquo; lined up to drive  shares higher.</li><li>Structural improvements in TiO2 prices and fluoropolymers could still  result in more than 30% upside for CC shares with a stable end-market, and perhaps more  than 50% if the market reaches a cyclical peak, Jefferies says.</li><li>Shares hit a 52-week high at $36.88 during yesterday's trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254111\" data-linked=\"Chemours upgraded to Buy at Jefferies on additional cyclical upside\" data-tweet=\"$CC - Chemours upgraded to Buy at Jefferies on additional cyclical upside https://seekingalpha.com/news/3254111-chemours-upgraded-to-buy-jefferies-on-additional-cyclical-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3254111-chemours-upgraded-to-buy-jefferies-on-additional-cyclical-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254105\" data-ts=\"1490790132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254105-vertex-pharmas-tezacaftor-ivacaftor-combo-successful-in-two-late-stage-studies-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex Pharma&#39;s tezacaftor/ivacaftor combo successful in two late-stage studies; shares ahead 17% premarket</a></h4><ul><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16783699-two-phase-3-studies-tezacaftor-ivacaftor-combination-treatment-met-primary-endpoints\" target=\"_blank\">announcement </a>of positive results from two Phase 3 clinical trials assessing the combination of tezacaftor and ivacaftor in patients with cystic fibrosis &#40;CF&#41;.</li><li>The 24-week EVOLVE study evaluated the combination in CF patients with two copies of the F508del mutation. It met the primary endpoint of a statistically valid improvement in lung function from baseline compared to placebo (p&lt;0.0001).</li><li>EXPAND, an eight-week crossover study, assessed the combination in CF patients with one copy of the F508del mutation and some CFTR function. The study also met its primary endpoint of a statistically valid improvement in lung function from baseline compared to placebo (p&lt;0.0001).</li><li>The company plans to file marketing applications in the U.S. and Europe in Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254105\" data-linked=\"Vertex Pharma&#39;s tezacaftor/ivacaftor combo successful in two late-stage studies; shares ahead 17% premarket\" data-tweet=\"$VRTX - Vertex Pharma&#39;s tezacaftor/ivacaftor combo successful in two late-stage studies; shares ahead 17% premarket https://seekingalpha.com/news/3254105-vertex-pharmas-tezacaftor-ivacaftor-combo-successful-in-two-late-stage-studies-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3254105-vertex-pharmas-tezacaftor-ivacaftor-combo-successful-in-two-late-stage-studies-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254097\" data-ts=\"1490789469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYBR\" target=\"_blank\">CYBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254097-cyberark-softwareplus-1_4-evercore-buys-dip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cyberark Software +1.4% as Evercore buys the dip</a></h4><ul><li>Evercore ISI's&nbsp;Kenneth Talanian upgraded to Outperform, with $60 price target suggesting just over&nbsp;<font color='green'>20% upside</font>.</li><li>The stock's&nbsp;<font color='red'>down just over 11%</font>&nbsp;from a high hit in mid-February.</li><li><a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a>&nbsp;<font color='green'>+1.4%</font>&nbsp;to $49.73 premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3254097\" data-linked=\"Cyberark Software +1.4% as Evercore buys the dip\" data-tweet=\"$CYBR - Cyberark Software +1.4% as Evercore buys the dip https://seekingalpha.com/news/3254097-cyberark-softwareplus-1_4-evercore-buys-dip?source=tweet\" data-url=\"https://seekingalpha.com/news/3254097-cyberark-softwareplus-1_4-evercore-buys-dip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254095\" data-ts=\"1490789340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254095-barclays-negative-on-groupon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays negative on Groupon</a></h4><ul> <li>Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) swings lower after Barclays starts off coverage on the tech stock with an <a href=\"https://twitter.com/RatingsNetwork/status/846833405006434304\" target=\"_blank\">Underweight rating</a>.</li> <li>\"After rapid growth in FY11-FY13, driving by heavy investment in subscriber acquisition and international expansion, the company has struggled to generate profitable growth over the last few years,\" warns Barclays.</li><li>\"The long-term value proposition of Groupon to consumers is also less certain at this time,\" reads the note.</li> <li>GRPN <font color='red'>-1.52%</font> premarket to $3.90 vs. a 52-week range of $2.92 to $5.94 and Barclay's price target of $3.60.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3254095\" data-linked=\"Barclays negative on Groupon\" data-tweet=\"$GRPN - Barclays negative on Groupon https://seekingalpha.com/news/3254095-barclays-negative-on-groupon?source=tweet\" data-url=\"https://seekingalpha.com/news/3254095-barclays-negative-on-groupon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254093\" data-ts=\"1490789215\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254093-f5-networksminus-3_5-deutsche-sees-30-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">F5 Networks -3.5% as Deutsche sees 30% downside</a></h4><ul><li>It's a fundamental call for fiscal 2018, not a conviction call on the March quarter report, <a href=\"https://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Downgrades+F5+Networks+%28FFIV%29+to+Sell%2C+Lowers+FY+20172018+EPS+Estimates/12716937.html\" target=\"_blank\">says analyst&nbsp;Vijay Bhagavath</a>.</li><li>He sees a deceleration in Product and Services revenues into fiscal 2018, and lowers his EPS view to $8.50 from $8.71. His 2017 estimate is trimmed to $8.08 from $8.10. 2019 remains at $8.75.</li><li>The new price target is $100, down from $120, and against yesterday's close of $147.13.</li><li><a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>&nbsp;<font color='red'>-3.5%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3254093\" data-linked=\"F5 Networks -3.5% as Deutsche sees 30% downside\" data-tweet=\"$FFIV - F5 Networks -3.5% as Deutsche sees 30% downside https://seekingalpha.com/news/3254093-f5-networksminus-3_5-deutsche-sees-30-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3254093-f5-networksminus-3_5-deutsche-sees-30-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254084\" data-ts=\"1490788658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACOR\" target=\"_blank\">ACOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254084-long-term-safety-data-positive-for-acordas-inhalable-parkinsons-candidate-cvtminus-301-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Long-term safety data positive for Acorda&#39;s inhalable Parkinson&#39;s candidate CVT-301; shares ahead 1% premarket</a></h4><ul><li>Acorda Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket, albeit on only 45 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16783837-acorda-announces-long-term-safety-data-cvtminus-301\" target=\"_blank\">announcement </a>of positive long-term safety data from two studies of CVT-301, an inhaled formulation of levodopa for the treatment of OFF periods in Parkinson's disease patients.</li><li>The two studies, CVT-301-005 and CVT-301-004E, involve ~700 subjects.</li><li>Data at week 52 in study 005 showed no statistical difference in lung function compared to control.</li><li>There was no control arm in study 004E. 49 participants completed their week 52 visit with no safety signals observed.</li><li>The most common adverse events in any study arm were cough (12.9%), nasopharyngitis (6.3%), dyskinesia (5.5%), fall (5.2%) and bone fracture (5.2%). There was one death (downing) judged unrelated to the study drug.</li><li>Data from both studies will be submitted for presentation at a future medical meeting.</li><li>The company plans to file an NDA next quarter and an MAA in Europe by year end.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3241998-acordas-cvtminus-301-successful-late-stage-pd-study-u-s-marketing-application-slated-q2\" target=\"_blank\">Acorda's CVT-301 successful in late-stage PD study; U.S. marketing application slated for Q2; shares up 13% premarket</a> (Feb. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3254084\" data-linked=\"Long-term safety data positive for Acorda&#39;s inhalable Parkinson&#39;s candidate CVT-301; shares ahead 1% premarket\" data-tweet=\"$ACOR - Long-term safety data positive for Acorda&#39;s inhalable Parkinson&#39;s candidate CVT-301; shares ahead 1% premarket https://seekingalpha.com/news/3254084-long-term-safety-data-positive-for-acordas-inhalable-parkinsons-candidate-cvtminus-301-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3254084-long-term-safety-data-positive-for-acordas-inhalable-parkinsons-candidate-cvtminus-301-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254077\" data-ts=\"1490787588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNOA\" target=\"_blank\">SNOA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254077-fda-clears-sonoma-pharmas-loyon-skin-descaler-shares-ahead-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears Sonoma Pharma&#39;s Loyon Skin Descaler; shares ahead 16% premarket</a></h4><ul><li>Thinly traded nano cap Sonoma Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNOA' title='Sonoma Pharmaceuticals, Inc.'>SNOA</a>) perks up&nbsp;<font color='green'>16</font>% premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16783809-sonoma-pharmaceuticals-receives-u-s-fda-clearance-loyon-skin-descaler-relief-scaling\" target=\"_blank\">announcement </a>that it has received 510(k) clearance from the FDA for its Loyon Skin Descaler to manage skin scaling experienced with a range of dermatoses.</li><li>The topically applied product is a patented combination of the dry emollient Cetiol CC and the medical silicone dimethicone.</li><li>U.S. market launch will commence this summer through the company's IntraDerm Pharmaceuticals direct salesforce.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254077\" data-linked=\"FDA clears Sonoma Pharma&#39;s Loyon Skin Descaler; shares ahead 16% premarket\" data-tweet=\"$SNOA - FDA clears Sonoma Pharma&#39;s Loyon Skin Descaler; shares ahead 16% premarket https://seekingalpha.com/news/3254077-fda-clears-sonoma-pharmas-loyon-skin-descaler-shares-ahead-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3254077-fda-clears-sonoma-pharmas-loyon-skin-descaler-shares-ahead-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254071\" data-ts=\"1490787124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATOS\" target=\"_blank\">ATOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254071-atossa-announces-equity-offering-shares-down-32-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atossa announces equity offering; shares down 32% premarket</a></h4><ul><li>Thinly traded nano cap Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics, Inc.'>ATOS</a>) is off&nbsp;<font color='red'>32%</font>&nbsp;premarket on increased volume in response its <a href=\"https://seekingalpha.com/pr/16783771-atossa-genetics-inc-prices-4000-000-public-offering\" target=\"_blank\">$4M public offering</a> of 664K Class A Units consisting of 664K shares of common stock and warrants to purchase 664K common shares at $0.9375 and and Class B Units.</li><li>Each Class B Unit consists of 3,502 shares of Series A Convertible Preferred Stock, each with a $1,000 face value and convertible into 1,333.33 common shares, and warrants to purchase the number of common shares into which the Series A is convertible into (at $0.9375).</li><li>Underwriters over-allotment is an additional 800K common shares and/or 800K warrants. Closing date is April 3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254071\" data-linked=\"Atossa announces equity offering; shares down 32% premarket\" data-tweet=\"$ATOS - Atossa announces equity offering; shares down 32% premarket https://seekingalpha.com/news/3254071-atossa-announces-equity-offering-shares-down-32-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3254071-atossa-announces-equity-offering-shares-down-32-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254069\" data-ts=\"1490787088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKX\" target=\"_blank\">SKX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254069-skechers-lower-after-susquehanna-warns-on-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skechers lower after Susquehanna warns on sales</a></h4><ul> <li>Susquehanna lowers Skechers (NYSE:<a href='https://seekingalpha.com/symbol/SKX' title='Skechers USA Inc.'>SKX</a>) to a Negative rating in a two-notch lowering after channel checks indicated sell-through weakness.</li> <li>Analyst Sam Poser expects domestic wholesale growth to fall short of Street expectations.</li> <li>The firm sets a price target of $25 to rep 17% downside potential for shares.</li> <li>The bear call on Skechers is the first from a major investment in over a year.</li> <li>Sources: Bloomberg and Marketbeat.com</li> <li>SKX <font color='red'>-4.21%</font> premarket to $28.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254069\" data-linked=\"Skechers lower after Susquehanna warns on sales\" data-tweet=\"$SKX - Skechers lower after Susquehanna warns on sales https://seekingalpha.com/news/3254069-skechers-lower-after-susquehanna-warns-on-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3254069-skechers-lower-after-susquehanna-warns-on-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254050\" data-ts=\"1490784934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254050-aveo-prices-stock-offering-0_50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO prices stock offering at $0.50</a></h4><ul><li>AVEO Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) <a href=\"https://seekingalpha.com/filing/3478319\" target=\"_blank\">prices </a>its public offering of 30M shares of common stock at $0.50 per share. Underwriters over-allotment is an additional 4.5M shares. Net proceeds should be ~$13.5M. Closing date is March 31.</li><li>Yesterday's close was $0.57.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254050\" data-linked=\"AVEO prices stock offering at $0.50\" data-tweet=\"$AVEO - AVEO prices stock offering at $0.50 https://seekingalpha.com/news/3254050-aveo-prices-stock-offering-0_50?source=tweet\" data-url=\"https://seekingalpha.com/news/3254050-aveo-prices-stock-offering-0_50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:55 AM </div></div></li>","count":71,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}